Ameriprise’s Soleno Therapeutics SLNO Stock Holding History

Ameriprise’s Portfolio SLNO Stock Details SLNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-8,471	Closed	-$284K	–	4239
2026 Q1	$284K	Sell	8,471 -254	-3%	-$9.96K	﹤0.01%	3772
2025 Q4	$404K	Sell	8,725 -121,855	-93%	-$6.68M	﹤0.01%	3705
2025 Q3	$8.83M	Buy	130,580 +111,545	+586%	+$8.27M	﹤0.01%	2008
2025 Q2	$1.59M	Sell	19,035 -11,678	-38%	-$874K	﹤0.01%	3067
2025 Q1	$2.19M	Sell	30,713 -4,393	-13%	-$214K	﹤0.01%	2845
2024 Q4	$1.58M	Buy	35,106 +7,223	+26%	+$374K	﹤0.01%	3050
2024 Q3	$1.41M	Sell	27,883 -5,741	-17%	-$275K	﹤0.01%	3074
2024 Q2	$1.37M	Buy	33,624 +2,484	+8%	+$105K	﹤0.01%	3025
2024 Q1	$1.33M	Buy	+31,140	New	+$1.41M	﹤0.01%	3050

Ameriprise's SLNO Position: Q2 2026 in Review

Ameriprise sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 8,471 shares — an estimated $284K sold.

Ameriprise first reported a position in SLNO in Q1 2024 and held it in 9 quarters. The position peaked at $8.83M in Q3 2025. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.

Ameriprise reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
Ameriprise sold 8,471 Soleno Therapeutics shares in Q2 2026, an estimated $284K.
Ameriprise first reported a position in Soleno Therapeutics in Q1 2024 and held it in 9 quarters.
Ameriprise's Soleno Therapeutics position peaked at $8.83M in Q3 2025.
0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.

Based on Ameriprise's 13F filing for Q2 2026, filed 14 Aug 2026.